Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Stavudine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.90 |
| ▸ | LMNA | P02545 | 1/20 | 0.90 |
| ▸ | ALB | P02768 | 1/20 | 0.90 |
| ▸ | POLB | P06746 | 1/20 | 0.90 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.90 |
| ▸ | BLM | P54132 | 1/20 | 0.90 |
| ▸ | TYMP | P19971 | 5/20 | 0.55 |
| ▸ | TK1 | P04183 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stavudine SCHEMBL987896 | 1.00 | ALDH1A1 (0.90) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL3420352 | 0.95 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL38661 | 0.95 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL7150054 | 0.95 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL9999805 | 0.95 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL3234890 | 0.95 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL8540086 | 0.95 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL18474938 | 0.95 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL6439535 | 0.95 | ALDH1A1 (1.00) | ALDH1A1LMNAALBPOLBADRA1A | |
| Stavudine SCHEMBL25259221 | 0.93 | ALDH1A1 (0.97) | ALDH1A1LMNAALBPOLBADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4190312-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE AGENTS INTO NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2023-06-07 | — | — | EP | claimed |
| EP-2428201-A1 | Oral administration of nucleoside monophosphates | Merck Serono S.A. (CH) | 2012-03-14 | — | — | EP | claimed |
| WO-2023104380-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2023-06-15 | — | — | WO | disclosed |
| EP-4190312-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE AGENTS INTO NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2023-06-07 | — | — | EP | disclosed |
| EP-3548087-A1 | NUCLEOSIDE TRIPHOSPHATE AND NUCLEOSIDE TRIPHOSPHATE ANALOGUE PRODRUGS | Universität Hamburg (DE) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018100137-A1 | NUCLEOSIDE TRIPHOSPHATE AND NUCLEOSIDE TRIPHOSPHATE ANALOGUE PRODRUGS | UNIVERSITÄT HAMBURG (DE) | 2018-06-07 | — | — | WO | disclosed |
| EP-2428201-A1 | Oral administration of nucleoside monophosphates | Merck Serono S.A. (CH) | 2012-03-14 | — | — | EP | disclosed |